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Casereportsfrominfanttwinssuggestthatabnormalgenomicimprintingmaybeoneoftheimportantcausesoftwindiscordance,
but it is unknown whether abnormal genomic imprinting occurs in the placenta. Therefore, we sought to determine the
relationship between the imprinting of insulin-like growth factor II (IGF-II) in placenta and twin discordance. We analyzed the
imprinting and promoter usage of IGF-II in placenta of normal twins (T0 group), weight discordance (T1 group), and phenotype
discordance (T2 group). We found the incidence of loss of imprinting (LOI) for IGF-II was higher in the T2 group than that in
the T0 and T1 groups, while there was no diﬀerence between T0 and T1 groups. The transcripts of promoter 3 were lower in
the T2 group than in the T0 and T1 groups, and lower in the twin placenta with LOI than in those with normal imprinting. Our
ﬁndingsindicatethatthepromoter3speciﬁcLOIoftheIGF-IIgenemaybecloselyrelatedwithphenotypediscordance,notweight
discordance.
1.Introduction
Twindiscordanceisacomplicationthatisuniquetomultiple
gestations. It is deﬁned as discordance in the growth pattern,
genotype, and phenotype of the twins. It can also just refer
to a birth weight discordance of more than 20% between
the twins [1]. Perinatal outcomes are worse in discordant
twins than in concordant twins. Discordant twins have been
found to have a signiﬁcant increase in perinatal death,
congenital anomalies, severe intracranial haemorrhage, neu-
rological morbidity, neonatal asphyxia, and respiratory dis-
tress [2, 3]. It is important to study the causes of twin
discordance in order to ﬁnd a treatment and improve the
prognosis.
Abnormal genomic imprinting may be one of the impor-
tant causes that results in twin discordance [4]. Genomic
imprinting is a special phenomenon that operates outside
of Mendel’s law and directs the nonrandom monoallelic
expression of speciﬁc autosomal genes according to their
parental origin. Loss of imprinting (LOI) is an epigenetic
alteration associated with the expression of the normally
repressed parental allele or silence of the normally active
allele. Imprinted genes play a key role in fetal and placental
growth, development of particular lineages, and behaviour
[5, 6]. It has been reported that an abnormal adjustment
of genomic imprinting may result in congenital anomalies,
some genetic diseases, and tumours [7, 8].
Insulin-like growth factor II (IGF-II) is one of the crucial
imprinted genes related to fetal growth and placental devel-
opment. It has 4 promoters and is expressed by the paternal
allele. The expression of IGF-II is very complex since its
imprintingisperiodic,aswellastissueandpromoterspeciﬁc.
Placental IGF-II can control fetal growth by modulating
placental development and nutritional transfusion [9]. The
LOI of the IGF-II gene is associated with fetal anomalies,
while mutations of the IGF-II gene promoter result in fetal
growth restriction [5].2 Obstetrics and Gynecology International
Table 1: Detail description of phenotype discordant in T2 group.
No. Chorion Twin A Twin B
Abnormity PM∗ I
∗∗ Abnormity PM
∗ I
∗∗
1 MCMA Transposition of the great vessels, ventricular septal defect AB AB N AB AB
2 DCDA Mass on right back AB AB N AB B
3 DCDA Hydatidiform mole AB AB N AB A
4 DCDA Intrauterine death AB AB N AB B
5 DCDA Anencephaly, spinal biﬁda, omphalocele AB AB N BB
6 MCDA Thoracogastroschisis, ventricular septal defect, aortic overriding AB AB N AB B
7 DCDA Fetal hydrops AB A N AA
8 DCDA Hypospadias AB A N AA
9 DCDA Abdominal-wall defect, spinal biﬁda AB A N BB
10 DCDA Double outlet right ventricle AB B N AB B
11 DCDA Omphalocele AA N AA
12 MCDA Acardiac twin AA N AA
13 MCDA Hypospadias AA N AA
∗AA, BB, and AB are three diﬀerent gene polymorphisms; AA/BB reﬂects homozygosity, and AB reﬂects heterozygosity. ∗∗A, B, and AB are three diﬀerent
imprinting states; A/B is the normal imprinting expression, while AB reﬂects loss of imprinting. Abbreviations: Polymorphisim (PM), Imprinting (I),
monochorionic monoamniotic twin (MCMA), dichorionic diamniotic twin (DCDA), monochorionic diamniotic twin (MCDA), and normal (N).
Few studies have examined the changes of IGF-II in twin
pregnancies, and there are no reports dealing with IGF-
II imprinting and promoter regulation in twin placenta.
It is uncertain whether IGF-II gene imprinting and pro-
moter regulation in the placenta are associated with twin
discordance. To clarify the role of imprinted IGF-II genes
in the pathogenesis of twin discordance, the imprinting and
promoter usage of IGF-II were studied.
2.MaterialsandMethods
2.1. Placenta Collection. Human placentas were collected
after birth in the ﬁrst Aﬃliated Hospital of Sun Yat-sen
University (Guangzhou, China). Eighty sets of twins were
enrolled, including 55 sets (64.71%) of normal twins (T0
group), 17 sets (20.00%) of twins with weight discordance
(T1 group), and 13 sets (15.29%) of twins with phenotype
discordance (T2 group). Weight discordance was deﬁned as
a birth weight discordance of more than 20% between the
twins. Phenotype discordance was deﬁned as being present
whenonlyoneofthetwinshadamalformationorbothtwins
haddiﬀerentabnormalities.DetaileddescriptionofT2group
was listed in Table 1.
For each twin, tissue samples were collected from under
the umbilical cord even when the twins shared the same
placenta. The tissues were washed with a saline solution to
remove maternal blood, then frozen in liquid nitrogen, and
stored at −80
◦C until analysis.
2.2. Preparation of Genomic DNA and RNA. Approximately
0.1g of the frozen tissues was homogenized using Teﬂon
tissue grinders. Genomic DNA (gDNA) was extracted using
phenol and chloroform. Total RNA isolation was performed
using TRI-reagent as suggested by the manufacturer (Molec-
ular Research Center Inc, Cincinnati, OH, USA). The quality
and quantity of the extracted RNA was assessed using an
Ultraviolet Bioanalyzer (Eppendorf, Hamburg, Germany).
Total RNA was treated with 10 Units of DNase I (Fermentas,
Vilnius, Lithuania) for 30minutes at 37
◦C to eliminate any
genomic DNA residue.
2.3. Identiﬁcation of Genomic Polymorphisms. To assess the
heterozygosity of the IGF-II gene, Apa I polymorphism
within exon 9 of IGF-II was screened. For PCR ampliﬁcation
of the IGF-II gene, the following primers were used: sense
strand (P1F), 5 CTTGGACTTTGAGTCAAATTGG-3 ,a n d
antisense strand (P1R), 5 -CCTCCTTTGGTCTTACTGGG-
3 .F o re a c h5 0 μlP C R ,2 μl gDNA, 5μl1 0 ×PCR buﬀer,
and 0.5 U Taq DNA Polymerase (TaKaRa, Dalian, China),
1μl sense and antisense primer (10pmol) and 1μld N T P s
(2.5mM) were ampliﬁed using an initial denaturation step
at 94
◦C for 7minutes, followed by 35 cycles of denaturation
at 94
◦ C for 30s, annealing at 60
◦ C for 40s with a 40s
extension, and a ﬁnal extension at 72
◦ Cf o r9 m i n u t e s .
T h ea m p l i ﬁ c a t i o nr e s u l t e di nag e n ef r a g m e n to f2 3 6 b p
whose allele had an ApaI restriction site at 173bp. The
PCR products were digested with the restriction enzyme
ApaI (New England Biolabs, Ipswich, UK) and loaded onto
3% agarose gel, which was followed by ethidium bromide
staining.
2.4. Allele-Speciﬁc Expression of IGF-II Genes. Allele-speciﬁc
expression of the IGF-II genes was examined using reverse
transcription-PCR (RT-PCR) followed by enzyme digestion
as described above. cDNA was synthesized using about 1μg
RNA and reverse transcriptase reagents (RevertAid H Minus
First Strand cDNA Synthesis Kit, Fermentas, Vilnius, Lithua-
nia) as suggested by the manufacturer. The resulting cDNA
samples were heated at 70
◦ C for 10minutes to inactivate the
reverse transcriptase, and then used for PCR ampliﬁcationObstetrics and Gynecology International 3
Table 2: Primers for promoter-speciﬁc expression of the IGF-II gene and internal control.
Name Sequence (5 -3 )L e n g t h
P1 (F) AG TCC TGA GGT GAG CTG CTG 181bp
P2 (F) ACC GGG CAT TGC CCC CAG TC 277bp
P3 (F) ACA TTC GGC CCC CGC GAC TC 201bp
P4 (F) TCC TCC TCC TCC TGC CCC AG 118bp
P1-4(R) CAA TGC AGC ACG AGG CGA AG
B-actin(F) GCG GGA AAT CGT GCG TGA CAT T 228bp
B-actin(R) GAT GGA GTT GAA GGT AGT TTG GTG
Table 3: Polymorphisms and imprinting of the IGF-II gene in placenta [n (%)].
Group Polymorphisim Imprinting
n AA/BB∗ AB∗ n A/B∗∗ AB∗∗
T0 group 110 41 (37.3) 69 (62.7) 68 56 (82.4) 12 (17.6)
T1 group 34 15 (44.1) 19 (55.9) 19 16 (84.2) 3 (15.8)
T2 group 26 10 (38.5) 16 (61.5) 16 9 (56.2) 7 (43.8)#
∗AA, BB, and AB are three diﬀerent gene polymorphisms; AA/BB reﬂects homozygosity, and AB reﬂects heterozygosity. ∗∗A, B, and AB are three diﬀerent
imprinting states; A/B is the normal imprinting expression, while AB reﬂects loss of imprinting. In the T0 group, the imprinting status could not be detected
in one case with AB gene polymorphism.# The frequency of loss of imprinting of the IGF-II gene was statistically signiﬁcantly diﬀerent between the T0 group
and the T2 group, P = .035.
as described above. The primers used for RT-PCR of IGF-
II were P1F and P1R as described above. The PCR products
were digested with ApaI (yielding either a 236bp fragment
or a 173 and 63bp fragment), electrophoresed through a 3%
agarose gel, and visualized with ethidium bromide.
2.5. Promoter-Speciﬁc Expressions of IGF-II. Promoter-
speciﬁc expressions of IGF-II were quantiﬁed using the
Absolute QPCR SYBR Green Mix plus ROX vial Kit (Abgene,
Epsom, UK) and the OpticonTM 2 continuous ﬂuorescence
detection system (MJ Research, Boston, MA, USA). The
primers used in real-time quantitative PCR (RT-PCR) for
each promoter speciﬁc expression of IGF-II are listed in
Table 2. The OpticonTM 2 was programmed as follows:
preincubation and denaturation of template cDNA for
15minutes at 94
◦ C; followed by 40 cycles of ampliﬁcation:
96
◦ C for 15s, 66
◦ Cf o r4 0s( P 1 )o r6 9
◦ Cf o r2 0s( P 2 )o r
60
◦ Cf o r3 0s( P 3 )o r6 3
◦ C for 30 s (P4), and 72
◦ Cf o r4 0s
(P1) or 20s (P2) or 30s (P3, P4). The melting curve analysis
wasperformedat65
◦ Cto98
◦ C,0.2
◦ C/read,2secondshold.
2.6. Statistics. The statistical analysis was performed using
the χ2 test, Fisher’s exact test, Student’s t-test, and ANOVA,
as appropriate. A P value of less than .05 was considered
signiﬁcant.
3. Results
3.1. Imprinting of IGF-II. For the imprinting study, DNA
specimensfromtheplacentawereﬁrstanalyzedforheterozy-
gosity using IGF-II gene polymorphisms at ApaI. Then, RT-
PCR products were analyzed for LOI by biallelic expression
of IGF-II ( Figure 1). The incidence of LOI of the IGF-II gene
was 43.8% in the T2 group placenta, which was higher than
1 2 3456 M
236bp
173bp
(a)
12 345M
236bp
173bp
(b)
Figure 1: Polymorphisms and imprinting of the IGF-II gene
in the placenta. (a) polymorphisms of IGF-II: 1 had type AA
homozygosity; 4 had type BB homozygosity; 2,3,5,6 had type AB
heterozygosity; and M, marker. (b) imprinting of IGF-II: 1, loss of
imprinting AB; 2–4, normal imprinting A; 5, normal imprinting B;
and M, marker.
that in the T0 and T1 groups (17.6% and 15.8%, resp., P<
.05) (Table 3). All LOI occurred in abnormal twins except in
one twin pair in which one twin was large for gestational age.
There were 4 cases of twin-twin transfusion syndrome,
including 1 acardiac twin. Among these 4 cases, 3 sets
were IGF-II homozygous, and 1 set, which was a Stage
III case of twin-twin transfusion syndrome, was IGF-II
heterozygous.Polyhydramniosoccurredintherecipienttwin
at 23 gestational weeks, and the maximal vertical amniotic
ﬂuid pocket was 16.5cm. The donor twin, whose bladder
was not visible, was a “stuck twin”, and the reverse end-
diastolic velocity of the umbilical artery could be seen.4 Obstetrics and Gynecology International
The woman decided to abort the pregnancy. After induction,
the imprinting status was analyzed. The donor twin had
normal imprinting expression, while the recipient twin had
LOI.
3.2.PromoterUsageofIGF-II. TheusageofIGF-IIpromoters
was similar in the T0, T1, and T2 groups. In each group,
among the 4 promoters, the transcripts of IGF-II gene
promoter 3 were the highest. The transcripts of IGF-II gene
promoter 3 in group T2 were signiﬁcantly lower than in
the T0 and T1 groups (P<. 05). The transcripts of IGF-
II gene promoter 3 were lower in twin placenta with LOI
than in those with normal imprinting (P<. 05). Intrapair
transcriptions of the 4 IGF-II gene promoters did not diﬀer
among the T0, T1, and T2 groups (P>. 05). There was a
positive correlation between the transcription of IGF-II gene
promoter 3 and the transcription of IGF-II gene promoter 4
(r = 0.229, P<. 05); there were no correlations with other
promoters (P>. 05).
4. Discussion
The paternally expressed, imprinted gene, IGF-II, located on
chromosome 11p15.5, encodes an autocrine growth factor
thatplays animportant role in embryonic growth. LOIofthe
IGF-II gene results in generalized constitutional overgrowth,
malformation, and a predisposition to the development
of speciﬁc embryonal tumours, most commonly Wilm’s
tumour.OurdatashowsthattheincidenceofLOIoftheIGF-
II gene was higher in T2 than in T0 and T1 group placenta,
and that all LOI occurred in abnormal twins, except in one
case. The incidence of LOI of the IGF-II gene was similar
in the T0 and T1 groups. Ravenel et al. [10], observed that
there was virtually complete segregation of the intralobar
nephrogenic rest (ILNR)-like and perilobar nephrogenic rest
(PLNR)-like tumours, depending on the imprinting status; 9
( 9 0 % )o f1 0P L N R - l i k et u m o u r sh a dL O I ,b u to n l y1( 6 . 7 % )
of 15 ILNR-like tumours had LOI, although the ILNR-
like and PLNR-like tumours were both Wilm’s tumours.
Thus, it is possible that the pathology involved in phenotype
discordant twins and weight discordant twins is diﬀerent,
and that LOI of the IGF-II gene may be closely related
with phenotype discordant twins, as in PLNR-like tumours.
Among the weight discordant twins, most of the small
fetuses were selective fetal growth restriction and the larger
ones were appropriate for gestational age, not overgrowth.
Furthermore, LOI of the IGF-II gene is much more relevant
to classical cases of Beckwith-Wiedemann syndrome (BWS)
or Silver-Russell syndrome (SRS) than to sporadic growth
deﬁciencies or overgrowth. These might be the possible
reasonwhyLOIofthe IGF-II geneinplacentaeis not amajor
contributor to weight discordance.
Placental IGF-II regulates the growth and transport
capacity of the placenta, thereby controlling the supply of
nutrients.Itmayalsodirectlyregulatethegrowthrateoffetal
tissues, thereby controlling fetal nutrient demand. LOI of the
IGF-II gene in the placenta might alter the balance between
placental and fetal growth and lead to fetal abnormalities.
It is reported that LOI of the IGF-II gene was relevant to
malformation like macroglossia and exomphalos, but not
other malformation. The malformation cases in our data
are diverse. It is not known whether fetal abnormalities
are due to a direct eﬀect of LOI of the IGF-II gene in the
placenta, or whether LOI of the IGF-II gene in the placenta
reﬂects LOI of the IGF-II gene in other fetal tissue, even
other gene imprinting. Further investigation of methylation
of other related imprinting genes is warranted to delineate
the possible mechanism of the diverse malformation. And
a larger series of phenotype discordant twins should be
followed up, in which each type of speciﬁc malformation is
represented by more cases.
During the life cycle of the organism, genomic imprints
change in characteristic ways. They undergo erasure, estab-
lishment, and maintenance of methylation imprints at
imprinting centers during germ cell and embryonic devel-
opment. Imprint patterns are maintained as chromosomes
duplicate and segregate, although there is genome-wide
demethylation after fertilization and a wave of de novo
methylation after implantation. Any changes in the microen-
vironment around the implantation could interfere with the
mechanismofmaintenance,sotwinsmightbemoresensitive
to get LOI with the epigenetic risks related to assisted
reproductive technologies and monochorionic twins. As
the changes occur around the implantation, imprints may
sometimes be discordant in twins, even in monozygotic
twins.
In our data, among 4 cases of twin-twin transfusion
syndrome, 3 sets were homozygous for IGF-II, and 1 set
was heterozygous (the donor twin had normal imprinting
expression, while the recipient twin had LOI). There have
been no reports dealing with the relationship between twin-
twin transfusion syndrome and LOI. Bajoria et al. [11],
found that fetal IGF-II levels in recipient twins with TTTS
were higher than those in donor twins. It was also reported
that IGFs may be involved in endothelial dysfunction [12].
Thus, more research is needed to determine whether LOI of
the IGF-II gene induced the abnormality of the vessels in the
twin placenta that leads to twin-twin transfusion syndrome
or was just related to the complications, such as twin-twin
transfusion syndrome with abnormal vessels.
IGF-II is transcribed from four distinct promoters, P1–
P4. It has been found that the fetal liver uses only three
promoters (P2, P3, and P4) for IGF-II transcription, with
the P3 promoter having the highest activity [13, 14]. Late
placental tissues of twin pregnancies show similar use of the
IGF-II promoter as in fetal liver. The P3 transcript levels
were higher than those of P4, while the P2 and P1 transcript
levels were low or zero. Compared to normal twins, the P3
transcript levels in the T2 group were dramatically lower.
This suggests that P3 plays the most important role in the
placenta, and that its abnormal activity may aﬀect fetal
growth.
Usually, P1 has biallelic expression, and P2-4 have
paternally monoallelic expression [15, 16]. It has been
proposed that IGF-II expression through promoter P1 could
explain the biallelic expression patterns in some neoplasms
[17, 18]. In these neoplasms, P1 plays the most importantObstetrics and Gynecology International 5
role, and most transcripts are from P1 rather than P2-4.
However, we found that, when there was LOI of the IGF-II
gene in twin placenta, the activity of P3, not P1, was greatly
changed.ThissuggeststhatmethylationchangesofP3induce
biallelic expression and decrease P3 activity. The mechanism
of LOI of the IGF-II gene in phenotype discordant twins may
be diﬀerent from that in some neoplasms. For phenotype
discordant twins, it was the biallelic expression of P3 and not
P1 that caused the discordance.
In conclusion, our data suggests that the promoter 3
speciﬁc LOI of the IGF-II gene may be closely related with
phenotype discordance, not weight discordance. Further
investigation of methylation of other related imprinting
genes and more phenotype discordant twins was warranted
to delineate the possible mechanism of the diverse malfor-
mation. Following up the weight discordance twins with LOI
will ﬁnd out whether they are predisposed to embryonal
tumours.
Acknowledgments
This work was supported by the Natural Science Foundation
of Guangdong Province (Project. no. 4009370) and Project
of Science and Technology of Guangdong Province (Project.
no. 2008B080701022).
References
[1] A. C. Fleischer, F. A. Manning, P. Jeanty, et al., Sonography in
Obstetrics and Gynecology, Principles & Practice, McGraw-Hill,
New York, NY, USA, 6th edition, 2001.
[ 2 ]V .Y .T .C h e u n g ,A .D .B o c k i n g ,a n dO .P .D a s i l v a ,“ P r e t e r m
discordant twins: what birth weight diﬀerence is signiﬁcant?”
American Journal of Obstetrics and Gynecology, vol. 172, no. 3,
pp. 955–959, 1995.
[ 3 ]H .R .Y a l c ¸in, C. G. Zorlu, A. Lembet, S. ¨ Ozden, and O.
G¨ okmen, “The signiﬁcance of birth weight diﬀerence in
discordant twins: a level to standardize?” Acta Obstetricia et
Gynecologica Scandinavica, vol. 77, no. 1, pp. 28–31, 1998.
[4] R. Weksberg, C. Shuman, O. Caluseriu et al., “Discordant
KCNQ1OT1 imprinting in sets of monozygotic twins discor-
dant for Beckwith-Wiedemann syndrome,” Human Molecular
Genetics, vol. 11, no. 11, pp. 1317–1325, 2002.
[5] M. Constˆ ancia, M. Hemberger, J. Hughes et al., “Placental-
speciﬁc IGF-II is a major modulator of placental and fetal
growth,” Nature, vol. 417, no. 6892, pp. 945–948, 2002.
[6] S. L. Thompson, G. Konfortova, R. I. Gregory, W. Reik,
W. Dean, and R. Feil, “Environmental eﬀects on genomic
imprinting in mammals,” Toxicology Letters, vol. 120, no. 1–3,
pp. 143–150, 2001.
[7] J. C. Williams, K. W. Brown, M. G. Mott, and N. J. Maitland,
“Maternal allele loss in Wilms’ tumour,” Lancet, vol. 1, no.
8632, pp. 283–284, 1989.
[8] A. Murrell, S. Heeson, W. N. Cooper et al., “An association
between variants in the IGF2 gene and Beckwith-Wiedemann
syndrome: interaction between genotype and epigenotype,”
Human Molecular Genetics, vol. 13, no. 2, pp. 247–255, 2004.
[9] A. L. Fowden, “The insulin-like growth factors and feto-
placental growth,” Placenta, vol. 24, no. 8-9, pp. 803–812,
2003.
[10] J. D. Ravenel, K. W. Broman, E. J. Perlman et al., “Loss of
imprinting of insulin-like growth factor-II (IGF2) gene in
distinguishing speciﬁc biologic subtypes of Wilms tumor,”
Journal of the National Cancer Institute, vol. 93, no. 22, pp.
1698–1703, 2001.
[ 1 1 ] R .B a j o r i a ,M .J .G i b s o n ,S .W a r d ,S .R .S o o r a n n a ,J .P .N e i l s o n ,
andM.Westwood,“Placentalregulationofinsulin-likegrowth
factor axis in monochorionic twins with chronic twin-twin
transfusion syndrome,” Journal of Clinical Endocrinology and
Metabolism, vol. 86, no. 7, pp. 3150–3156, 2001.
[12] F. Miceli, A. Tropea, F. Minici et al., “Eﬀects of insulin-like
growth factor I and II on prostaglandin synthesis and plas-
minogen activator activity in human umbilical vein endothe-
lial cells,” Journal of Clinical Endocrinology and Metabolism,
vol. 90, no. 1, pp. 372–378, 2005.
[13] X. Li, H. Cui, B. Sandstedt, H. Nordlinder, E. Larsson, and T. J.
Ekstr¨ om, “Expression levels of the insulin-like growth factor-
IIgene(IGF2)inthehumanliver:developmentalrelationships
of the four promoters,” Journal of Endocrinology, vol. 149, no.
1, pp. 117–124, 1996.
[14] X. Li, Z. Nong, C. Ekstr¨ om et al., “Disrupted IGF2 promoter
control by silencing of promoter P1 in human hepatocellular
carcinoma,” Cancer Research, vol. 57, no. 10, pp. 2048–2054,
1997.
[15] T. H. Vu and A. R. Hoﬀman, “Promoter-speciﬁc imprinting
of the human insulin-like growth factor-II gene,” Nature, vol.
371, no. 6499, pp. 714–717, 1994.
[16] T. J. Ekstrom, H. Cui, X. Li, and R. Ohlsson, “Promoter-
speciﬁc IGF2 imprinting status and its plasticity during
human liver development,” Development, vol. 121, no. 2, pp.
309–316, 1995.
[17] C.-L.Chen,S.-M.Ip,D.Cheng,L.-C.Wong,andH.Y.S.Ngan,
“Loss of imprinting of the IGF-II and H19 genes in epithelial
ovariancancer,”ClinicalCancerResearch,vol.6,no.2,pp.474–
479, 2000.
[18] S. J. Kim, S. E. Park, C. Lee et al., “Alterations in promoter
usageandexpressionlevelsofinsulin-likegrowthfactor-IIand
H19genesincervicalcarcinomaexhibitingbiallelicexpression
of IGF-II,” Biochimica et Biophysica Acta, vol. 1586, no. 3, pp.
307–315, 2002.